The latest national myeloma trial, Myeloma XII, has recently opened for patient recruitment. The aim of this Phase III trial is to determine whether ixazomib (Ninlaro®) has a significant impact on the depth and duration of response when used as an augmented conditioning treatment in salvage autologous stem cell transplantation (ASCT) and then as post-transplant consolidation and maintenance treatment. Ixazomib is also being used as part of re-induction treatment in combination with thalidomide and dexamethasone. The trial aims to recruit over 400 myeloma patients at first relapse following a previous ASCT, with up to 70 centres around the UK participating.


Read article